Switching From a GLP-1 to Contrave: What to Know | Harbor

Millions of Americans started taking injectable GLP-1 receptor agonists over the past few years with real optimism. For many, the results include significant weight loss, better blood sugar control, and a quieter relationship with food cravings. But the reality of staying on these medications long-term has proven far more complicated than the initial prescriptions suggested. Between 50% and 75% of patients stop GLP-1 therapy within the first year. Among more than 125,000 patients who started GLP-1 receptor agonists, 64.8% of those using the drugs for weight management discontinued within 12 months. If you're among the patients stepping away from an injectable GLP-1, the question of what comes next deserves a thoughtful answer.

Contrave waist-slimming result depicted as a woman in a gray crop top measures her midsection with a yellow tape measure against a dark background.

Why So Many Patients Are Moving Away From Injectable GLP-1s

The various factors that may influence a patient's or provider's decision to switch from a GLP-1 receptor agonist to Contrave include individual health profiles, preferences, and prior medication responses. The surge in GLP-1 discontinuation is driven by the convergence of several persistent barriers that make long-term use unsustainable for a large share of patients.

Cost remains the dominant obstacle. Brand-name GLP-1 injectables carry list prices that can top $1,000 per month. 54% of GLP-1 users struggle to afford their medication. While recent agreements between the White House and major pharmaceutical manufacturers have capped prices at $350 per month for some populations, with Medicare beneficiaries paying a $50 monthly copay, these changes are still rolling out unevenly. Meanwhile, several state Medicaid programs rolled back GLP-1 coverage in 2025, and some commercial plans followed suit. The number of people with no commercial insurance coverage for certain GLP-1 weight-loss medications increased by 42% in 2026 compared to the previous year, leaving over 41 million people without coverage.
Side effects take a cumulative toll. The potential side effects and safety concerns associated with both GLP-1 agonists and Contrave are particularly relevant when switching between them. Nausea, vomiting, diarrhea, constipation, and abdominal pain are common enough that real-world studies report gastrointestinal adverse events in between 40% and 70% of GLP-1-treated patients. For some, these effects diminish over time. For others, they persist at levels that make daily life genuinely difficult, eventually outweighing the benefits of weight loss.
Supply chain instability creates treatment gaps. Even patients who can afford their medication and tolerate it well have faced periods where they simply couldn't get their prescriptions filled. These involuntary interruptions disrupt the consistent dosing required by GLP-1 therapies for sustained results, and each gap increases the risk of partial weight regain, which erodes patient motivation.

While self-injection has become normalized in diabetes management, not all weight-management patients are comfortable with needles, particularly when facing the prospect of indefinite treatment.

What Happens to Your Body When You Stop a GLP-1

Understanding the physiological consequences of GLP-1 discontinuation is essential context for anyone considering a switch to Contrave, because it shapes both the timeline and the expectations for your next treatment phase. A systematic review and meta-analysis of multiple studies found that GLP-1 discontinuation was associated with a pooled mean weight regain of 5.63 kg. The regain was notably more pronounced with certain agents. Semaglutide-treated patients experienced an average weight regain of 8.21 kg, compared with 4.29 kg with liraglutide. Longer follow-up periods revealed an even greater rebound: patients tracked beyond 26 weeks regained an average of 7.31 kg, compared with 2.51 kg for those followed for shorter periods.

The STEP 1 trial extension demonstrated that participants regained approximately two-thirds of the weight they had lost within a year of stopping semaglutide. This wasn't simply about returning hunger. Cardiometabolic improvements also reversed. Semaglutide discontinuation was associated with increases in waist circumference (3.80 cm on average) and systolic blood pressure (7.09 mmHg).

However, a March 2026 study offered an important real-world counterpoint. Analyzing nearly 8,000 patients, the researchers found that weight regain following GLP-1 discontinuation was neither as rapid nor as consistent as randomized controlled trial data had predicted. The difference? Many patients didn't simply stop treatment altogether. They restarted their medication after a gap, switched to alternative therapies, or engaged more actively with lifestyle modifications during the off-medication period. This finding matters for patients considering Contrave. Transitioning to a different pharmacological approach may help preserve at least some of the progress achieved on a GLP-1.

How Contrave Works: A Different Mechanism Entirely

Contrave isn't a GLP-1 receptor agonist. It doesn't mimic gut hormones, slow gastric emptying, or signal satiety through the same pathways as semaglutide and tirzepatide. Understanding this distinction is critical because switching to Contrave represents a fundamentally different pharmacological strategy.

Contrave combines two active ingredients: naltrexone (an opioid antagonist) and bupropion (an aminoketone antidepressant that also inhibits dopamine and norepinephrine reuptake). Their synergy targets the brain's appetite regulation and reward systems through two primary mechanisms.

In the hypothalamus, pro-opiomelanocortin (POMC) neurons play a central role in appetite regulation. These neurons release two key substances: alpha-melanocyte-stimulating hormone (α-MSH), which suppresses appetite, and beta-endorphin, which creates an autoinhibitory feedback loop that effectively shuts down the appetite-suppressing signal. Bupropion stimulates POMC neurons to release α-MSH — but as a standalone agent, its effect is limited because the body's own beta-endorphin feedback dampens the signal. Naltrexone blocks this feedback loop, preventing the body from "turning off" appetite suppression. While each drug, individually, increased POMC neuron firing to approximately 3–4 Hz in preclinical models, the combination drove firing rates to approximately 11 Hz, a roughly threefold amplification, illustrating the synergistic nature of the pairing.

Beyond hypothalamic appetite control, the naltrexone-bupropion combination modulates the brain's mesolimbic dopamine reward pathways. This is particularly relevant for patients whose weight management challenges are driven less by physical hunger and more by food cravings, emotional eating, or difficulty controlling portions — patterns that overlap with dopaminergic signaling associated with addictive behaviors. Patients who are differentially affected by food cravings may see better outcomes with treatments targeting both homeostatic and hedonic food-consumption pathways. This dual mechanism is what distinguishes Contrave from GLP-1 therapies and explains why some patients who didn't respond optimally to gut-hormone-based approaches may respond differently to a neurological one.

What the Clinical Evidence Shows About Contrave's Efficacy

Setting realistic expectations requires looking at the data directly. Contrave's efficacy has been established through the Contrave Obesity Research (COR) program, a series of four 56-week, multicenter, randomized, double-blind, placebo-controlled phase 3 trials enrolling 4,536 patients.

The results across all four pivotal trials demonstrated superiority over placebo. In the COR-II trial, patients on naltrexone/bupropion achieved a mean weight loss of 6.4% to 6.5% of baseline body weight at 56 weeks, compared to 1.2% to 1.9% in the placebo group. The placebo-subtracted mean weight loss ranged from 3.28% to 4.81% across the four studies, and all met their co-primary endpoints. At the individual patient level, approximately 50.5% of treatment participants in the COR-II trial achieved at least 5% weight loss by week 56, compared to 17.1% on placebo. Around 42% of patients across the COR program lost 10% or more of their baseline body weight, a threshold generally associated with meaningful improvements in obesity-related health conditions.

The Practical Side of Switching: Titration, Timing, and What to Expect

Titration Schedule

Contrave uses a four-week dose escalation to minimize early side effects. During Week 1, you take one tablet (8 mg naltrexone / 90 mg bupropion) each morning. In Week 2, you add a second tablet in the evening. Week 3 adds a second morning tablet, and by Week 4, you reach the full maintenance dose of two tablets twice daily, 32 mg naltrexone and 360 mg bupropion per day. The most common side effect is nausea, which tends to peak during the escalation phase and subside as the body adjusts. Starting at full dose would significantly increase the likelihood and severity of early adverse effects and undermine patient adherence.

Managing the Transition Window

The period between stopping a GLP-1 and reaching Contrave's therapeutic dose is the most vulnerable window. GLP-1 effects on appetite suppression and gastric emptying fade relatively quickly after the last injection, while Contrave takes three to four weeks to reach full dosing. During this gap, the return of hunger signals and cravings can feel abrupt, particularly for patients who experienced strong appetite suppression on their GLP-1.

GLP-1 medications result illustrated as a slim woman in a pink crop top and drawstring pants measures her bare midriff with a yellow tape measure.

Working with your prescribing provider to time the transition thoughtfully can help. Some clinicians recommend starting Contrave titration while still experiencing residual GLP-1 effects, rather than waiting until they've fully cleared. This isn't a universal recommendation and depends on individual patient factors, so it's a conversation worth having with your healthcare team.

Side Effects to Anticipate

Contrave's side-effect profile differs substantially from GLP-1s. While GLP-1 side effects center on the gastrointestinal tract (nausea, vomiting, diarrhea), Contrave's most common adverse effects also include constipation, dizziness, dry mouth, headache, and insomnia. Patients may also develop elevated blood pressure or heart rate, with the risk potentially greater during the first three months of treatment.

Setting Realistic Expectations: What Contrave Will and Won't Do

Switching to Contrave with GLP-1-calibrated expectations sets you up for disappointment. Setting appropriate expectations from the start is one of the most important factors in a successful transition.

Contrave will likely reduce food cravings and improve your sense of control around eating. The clinical trials consistently showed improvements in self-reported eating behavior, and the pharmacological basis for this is well-established. If cravings and hedonic eating are significant contributors to your weight management challenges, this benefit may be substantial.
Contrave will not replicate the dramatic appetite suppression that GLP-1s provide. GLP-1 receptor agonists work partly by slowing gastric emptying, creating a prolonged physical sensation of fullness that many patients describe as transformative. Contrave doesn't act on the gut in this way. You'll likely feel hungrier on Contrave than you did on your GLP-1, particularly in the early weeks. The mechanism is subtler, a reduction in the drive to eat rather than a physical inability to eat large quantities.
Contrave is an oral medication that changes the treatment experience. There are no injection-site reactions, no cold-chain storage requirements, and no weekly injection schedule to maintain. For patients who found the injectable format burdensome or anxiety-inducing, this is a meaningful quality-of-life improvement. The tradeoff is that Contrave requires daily dosing, which demands more consistent daily adherence than a once-weekly injection.
Contrave is generally more affordable than brand-name GLP-1 injectables. While the list price can exceed $500 per month without insurance, savings programs can bring the cost to approximately $99 per month or less. Compared to GLP-1 medications that frequently exceed $1,000 per month without coverage, the cost barrier is substantially lower.

Alternative Weight Management Options

There are other weight management strategies available, including medications, supplements, and surgical options, for patients considering or undergoing a switch in their pharmacological treatment. Beyond GLP-1s and Contrave, other FDA-approved medications, such as phentermine or standalone naltrexone, may be considered, each with distinct mechanisms and varying suitability depending on individual health profiles. Medical-grade supplements, including high-quality protein, essential vitamins, probiotics, and omega-3 fatty acids, can support metabolism, preserve muscle mass, and address nutritional gaps during weight loss. For those seeking more substantial or lasting results, bariatric surgical procedures like gastric sleeve surgery offer a powerful option, fundamentally altering hunger cues and promoting significant, sustained weight loss. The best approach is often a personalized combination of these strategies, tailored in consultation with a healthcare provider. Exploring all available options empowers patients to find a sustainable, effective path forward, even as their medication needs evolve.

Building a Comprehensive Transition Strategy

Not all clinicians have deep familiarity with the practical nuances of transitioning between weight-management drug classes. A provider experienced in obesity medicine can help you time the switch, set appropriate benchmarks, and monitor for complications specific to the transition period. Telehealth platforms like Harbor have made it easier to access physician-guided weight management consultations from home, particularly valuable for patients in areas where obesity medicine specialists are scarce or where waitlists are long.

Beyond stepping on a scale, track metrics that capture the full picture of how Contrave is working for you. Waist circumference, energy levels, sleep quality, exercise capacity, and our subjective experience of food cravings and eating control all provide useful signals. The cravings and eating behavior metrics are particularly relevant for Contrave, given its mechanism of action, and improvements in these areas may precede visible changes in scale.

Obesity is a chronic condition, and effective management typically requires sustained treatment. Whether that means staying on Contrave long-term, eventually returning to a GLP-1 when access or affordability improves, or combining approaches under medical supervision, the most important thing is maintaining continuity of care rather than cycling through periods of treatment and abandonment.

Contrave treatment outcome shown as a slim woman pulls back the loose waistband of her oversized light-wash distressed jeans.

Frequently Asked Questions

Making the switch from a GLP-1 agonist to Contrave is a significant decision, and it’s natural to have questions about what to expect. Below, we address some of the most common concerns patients have during this transition.

Will I regain weight after stopping my GLP-1 medication?

Some weight regain is common after discontinuing a GLP-1, but transitioning to Contrave or adopting other healthy habits can help preserve weight loss and reduce the risk of rapid rebound.

How soon should I start Contrave after stopping my GLP-1?

Discuss the timing with your healthcare provider. Some patients may benefit from starting Contrave titration while GLP-1 effects linger, minimizing gaps in appetite control.

What side effects should I expect with Contrave?

Common side effects include nausea, headache, constipation, dizziness, dry mouth, and insomnia. Most side effects peak during the first few weeks and often subside as your body adjusts.

Will Contrave suppress my appetite as much as a GLP-1?Contrave reduces cravings and improves eating control, but it doesn’t provide the same strong physical fullness as GLP-1s. You may notice a subtler effect on appetite.

Is Contrave easier to take than injectable GLP-1s?

Contrave is taken orally as daily tablets, eliminating the need for injections or refrigeration. However, daily adherence is important for the best results.

How long does it take for Contrave to reach full effectiveness?

Contrave requires a four-week titration period to reach the full maintenance dose. Appetite and craving control typically improve as you reach the target dose.

Can I take Contrave if I have other health conditions?

Your provider will review your medical history to ensure Contrave is safe for you, especially if you have a history of high blood pressure, seizures, or certain psychiatric conditions.

Will my insurance cover Contrave?

Contrave is often more affordable than GLP-1s and may be covered by insurance or available through savings programs. Check with your provider and pharmacy for options.

What can I do to manage increased hunger during the transition?

Plan for healthy meals, stay hydrated, and use behavioral strategies to manage cravings. Your provider can help with personalized tips during the adjustment period.

Should I expect the same weight loss results on Contrave as with GLP-1s?

Contrave can support meaningful weight loss, especially for patients struggling with cravings, but results may differ from those experienced on GLP-1s. Set realistic expectations and track your progress.

Switching from a GLP-1 injectable to Contrave is not a lateral move. It's a transition between two fundamentally different pharmacological approaches to weight management, each with distinct mechanisms of action, efficacy profiles, side effects, and practical considerations. For patients leaving GLP-1 therapy due to cost, side effects, supply issues, or insurance barriers, Contrave offers a viable oral alternative that targets the neurological drivers of overeating rather than the gut-hormone pathways that GLP-1s leverage. The clinical evidence supports meaningful weight loss, with particular strengths in craving reduction and control of eating behavior. The cost profile is more accessible, the delivery method eliminates injection-related barriers, and the four-week titration provides a structured on-ramp. The patients most likely to succeed in this transition are those who approach it with calibrated expectations, a strong provider relationship, and a commitment to the behavioral foundations that support any pharmacological intervention. The goal is to find a sustainable path forward that keeps you progressing rather than regressing.

Sources: